Scores by kind of claim
Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.
-
Factual claims
Statements about the present or the past, checked against the record: did they hold up?
82 76 88 -
Predictions
Statements about events outside the person's control, checked once they fell due: did they come true?
61 47 75 -
Promises
Commitments to the person's or organisation's own future action, with something to deliver: was it delivered?
67 46 85
All types combined: 77 (likely 72 to 82, high confidence), from 84 claims: 63 factual claims, 16 predictions, 5 promises. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.
Nate Silver's claims
37 claims
“It sure seems very likely that people who got one dose of J&J would benefit from getting a booster of Pfizer or Moderna.”
Nate Silver, writing on X 29 June 2021 Post by @NateSilver538 on X, 2021-06-29 (X)
It seems very likely that people who received one dose of the J&J COVID vaccine would benefit from a Pfizer or Moderna booster.
Mostly true True in substance, wrong in a detail.
The second judge would not resolve this claim; the verdict shown is the first judge's.
What would count as true or false
A hedged ('very likely') prediction, judged against clinical and regulatory evidence available by mid-2022. True: studies (e.g. NIH mix-and-match trials or real-world effectiveness data) show that J&J single-dose recipients who got a Pfizer or Moderna booster had meaningfully higher immune responses or protection than those with no booster, and regulators (FDA/CDC) authorized or recommended mRNA boosters for J&J recipients. Mostly true: a clear benefit is shown, but on narrower measures only (e.g. antibody levels without clinical outcome data). Mixed: evidence of benefit is inconsistent or limited to some subgroups. Mostly false: mRNA boosters gave little benefit over a J&J booster or no booster for most recipients. False: evidence shows no benefit, or net harm, from an mRNA booster for J&J recipients.
Evidence
- Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022 CDC, Morbidity and Mortality Weekly Report (MMWR) · 1 April 2022
“VE against COVID-19–associated emergency department/ urgent care visits was 24% after 1 Jansen dose, 54% after 2 Jansen doses, and 79% after 1 Janssen/1 mRNA dose, compared to 83% after 3 mRNA doses.”
- Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming Erasmus University Rotterdam research portal (pure.eur.nl); published in NEJM · 10 March 2022
“Boosting with any available vaccine was better than not boosting.”
- Mix-and-match trial finds additional dose of COVID-19 vaccine safe, immunogenic National Institutes of Health (NIAID media advisory) · 26 January 2022
“For each primary EUA COVID-19 vaccine, heterologous boosts elicited similar or higher antibody responses as compared to responses to a homologous booster.”
Reasoning
A CDC study from the VISION Network (E1) estimated vaccine effectiveness against emergency department and urgent care visits from December 2021 to March 2022. It was 79% after one Janssen dose plus an mRNA booster, against 24% after a single Janssen dose. An NEJM study (E2) found that boosting J&J-primed people with any available vaccine was better than not boosting. The NIH mix-and-match trial (E4) found that mixed-vaccine boosters produced similar or higher antibody responses than same-vaccine boosters. Together these show a clear benefit, including on clinical outcomes. However, none of the evidence shows that the FDA or CDC authorized or recommended mRNA boosters for J&J recipients, which the criteria require for a fully true verdict.
Cite this claim
Nate Silver, “It seems very likely that people who received one dose of the J&J COVID vaccine would benefit from a Pfizer or Moderna booster.” (said 29 June 2021). Verdict: mostly true. Reliability API, claim c_dc12ab492306, method 0.1.0+28da144b. https://epistacklabs.com/claims/c_dc12ab492306
Claims without a verdict
Is a verdict here wrong, or do you speak for Nate Silver? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.